Financial Support: Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065257.
Rethinking Headache Chronification
Article first published online: 30 MAY 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 53, Issue 6, pages 901–907, June 2013
How to Cite
Turner, D. P., Smitherman, T. A., Penzien, D. B., Lipton, R. B. and Houle, T. T. (2013), Rethinking Headache Chronification. Headache: The Journal of Head and Face Pain, 53: 901–907. doi: 10.1111/head.12127
Conflicts of Interest: Dana P. Turner: Ms. Turner receives research support from Merck; Todd A. Smitherman: Dr. Smitherman receives research support from Merck; Donald B. Penzien: Dr. Penzien receives research support from Merck; Richard B. Lipton: Dr. Richard B. Lipton receives research support from the NIH [PO1 AG03949 (Program Director), PO1AG027734 (Project Leader), RO1AG025119 (Investigator), RO1AG022374-06A2 (Investigator), RO1AG034119 (Investigator), RO1AG12101 (Investigator), K23AG030857 (Mentor), K23NS05140901A1 (Mentor), and K23NS47256 (Mentor), the National Headache Foundation, and the Migraine Research Fund; serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache, has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics (a company without commercial products); serves as consultant, advisory board member, or has received honoraria from: Allergan, American Headache Society, Autonomic Technologies, Boehringer-Ingelheim Pharmaceuticals, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Vedanta, Zogenix. Timothy T. Houle: Dr. Houle receives research support from GlaxoSmithKline and Merck.
To download a podcast featuring further discussion of this article, please visit http://www.headachejournal.org
- Issue published online: 30 MAY 2013
- Article first published online: 30 MAY 2013
- Manuscript Accepted: 21 MAR 2013
- National Institute of Neurological Disorders and Stroke of the National Institutes of Health. Grant Number: R01NS065257
- headache chronification;
- chronic migraine;
The objective of this series is to examine several threats to the interpretation of headache chronification studies that arise from methodological issues. The study of headache chronification has extensively used longitudinal designs with 2 or more measurement occasions. Unfortunately, application of these designs, when combined with the common practice of extreme score selection as well as the extant challenges in measuring headache frequency rates (eg, unreliability, regression to the mean), induces substantive threats to accurate interpretation of findings. Partitioning the amount of observed variance in rates of chronification and remission attributable to regression artifacts is a critical yet previously overlooked step to learning more about headache as a potentially progressive disease. In this series on rethinking headache chronification, we provide an overview of methodological issues in this area (this paper), highlight the influence of rounding error on estimates of headache frequency (second paper), examine the influence of random error and regression artifacts on estimates of chronification and remission (third paper), and consider future directions for this line of research (fourth paper).